Alnylam Pharmaceuticals, Inc. employees and revenue per employee

ALNY · Biotechnology · $29.4B market cap

Alnylam Pharmaceuticals, Inc. had 2,500 employees at the end of fiscal Dec 2025, up 12.1% from a year earlier. Revenue for the year was $3.71B, up 65.2% from a year earlier, or $1.49M per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

2,500

+12.1% YoY

Revenue

$3.71B

+65.2% YoY

Revenue / employee

$1.49M

Peer median $602K

Rank in industry

9 of 39

Biotechnology

Open roles

115

46 per 1,000 staff

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016
042498497'16'17'18'19'20'21'22'23'24'25Revenue 7875Staff 486

Hover a year for the numbers.

ALNY employees and revenue by fiscal year
Year endingEmployeesRevenuePer employeeStaff YoYRevenue YoY
Dec 20252,500$3.71B$1.49M+12.1%+65.2%
Dec 20242,230$2.25B$1.01M+6.2%+23.0%
Dec 20232,100$1.83B$871K+4.9%+76.2%
Dec 20222,002$1.04B$518K+20.2%+22.9%
Dec 20211,665$844M$507K+14.6%+71.3%
Dec 20201,453$493M$339K+9.8%+124.3%
Dec 20191,323$220M$166K+24.2%+193.4%
Dec 20181,065$74.9M$70K+42.2%-16.7%
Dec 2017749$89.9M$120K+45.7%+90.7%
Dec 2016514$47.2M$92K——

Open roles on its job board: 115 (46 per 1,000 staff, against its latest annual headcount), as of 2026-10-07. Tracked since 2026-10-03. No 90 day change yet.

Employees, last six fiscal years
1,453'201,665'212,002'222,100'232,230'242,500'25
Revenue per employee, last six fiscal years
$339K'20$507K'21$518K'22$871K'23$1.01M'24$1.49M'25

Alnylam Pharmaceuticals, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

CompanyEmployeesRevenueRevenue / employeeShape
UTHR
United Therapeutics Corporation
1,400$3.18B$2.27MEfficient growth
EXEL
Exelixis, Inc.
1,077$2.32B$2.15MLeaner
INCY
Incyte Corporation
2,844$5.14B$1.81MEfficient growth
PTCT
PTC Therapeutics, Inc.
991$1.73B$1.75MEfficient growth
ALNY
Alnylam Pharmaceuticals, Inc.
2,500$3.71B$1.49MEfficient growth
NBIX
Neurocrine Biosciences, Inc.
2,000$2.86B$1.43MEfficient growth
BMRN
BioMarin Pharmaceutical Inc.
3,221$3.22B$1.00MEfficient growth
MRNA
Moderna, Inc.
4,700$1.94B$414KContracting
FTRE
Fortrea Holdings Inc.
14,300$2.72B$190KLeaner
Every Healthcare company

Questions about Alnylam Pharmaceuticals, Inc.

How many employees does Alnylam Pharmaceuticals, Inc. have?
Alnylam Pharmaceuticals, Inc. reported 2,500 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 12, 2026. That is up 12.1% from a year earlier.
What is Alnylam Pharmaceuticals, Inc.'s revenue per employee?
Alnylam Pharmaceuticals, Inc. brought in $3.71B of revenue in fiscal Dec 2025, which is $1.49M per employee. That ranks 9 of 39 companies we track in Biotechnology, where the median is $602K.
Is Alnylam Pharmaceuticals, Inc. hiring?
Alnylam Pharmaceuticals, Inc.'s public job board listed 115 open roles on October 7, 2026, about 46 per 1,000 staff.
Where do these numbers come from?
Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

Compare ALNY with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Source: employee counts and revenue as stated in Alnylam Pharmaceuticals, Inc.'s annual reports (Form 10-K), latest filed February 12, 2026. This is data, not a recommendation to buy or sell ALNY.